InvestorsObserver
×
News Home

How Will the Market React to Aerie Pharmaceuticals Inc (AERI) Stock Getting a Bearish Rating

Thursday, October 21, 2021 11:07 AM | InvestorsObserver Analysts

Mentioned in this article

How Will the Market React to Aerie Pharmaceuticals Inc (AERI) Stock Getting a Bearish Rating

Overall market sentiment has been down on Aerie Pharmaceuticals Inc (AERI) stock lately. AERI receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Aerie Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AERI!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With AERI Stock Today?

Aerie Pharmaceuticals Inc (AERI) stock is trading at $11.77 as of 11:03 AM on Thursday, Oct 21, a gain of $0.17, or 1.47% from the previous closing price of $11.60. The stock has traded between $11.53 and $11.93 so far today. Volume today is below average. So far 341,239 shares have traded compared to average volume of 1,024,742 shares. To screen for more stocks like Aerie Pharmaceuticals Inc click here.

More About Aerie Pharmaceuticals Inc

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roclatan. The company mainly operates in North America. Click Here to get the full Stock Report for Aerie Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App